Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
11/15/2026
Impact: -75
Healthcare
Summit Therapeutics said the FDA issued a Complete Response Letter for its application seeking approval of ivonescimab with platinum-containing chemotherapy for certain patients with locally advanced or metastatic NSCLC previously treated with EGFR tyrosine kinase inhibitors. The FDA determined the application cannot be approved in its current form, and Summit must address the issues raised to determine the next steps in the regulatory process. The article did not report financial figures or a stock-price reaction.
AI summary, not financial advice
Share: